The Role of Base Excision Repair in the Sensitivity and Resistance to Temozolomide-Mediated Cell Death
- 15 July 2005
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 65 (14), 6394-6400
- https://doi.org/10.1158/0008-5472.can-05-0715
Abstract
DNA-alkylating agents have a central role in the curative therapy of many human tumors; yet, resistance to these agents limits their effectiveness. The efficacy of the alkylating agent temozolomide has been attributed to the induction of O6-MeG, a DNA lesion repaired by the protein O6-methylguanine-DNA methyltransferase (MGMT). Resistance to temozolomide has been ascribed to elevated levels of MGMT and/or reduced mismatch repair. However, >80% of the DNA lesions induced by temozolomide are N-methylated bases that are recognized by DNA glycosylases and not by MGMT, and so resistance to temozolomide may also be due, in part, to robust base excision repair (BER). We used isogenic cells deficient in the BER enzymes DNA polymerase-beta (pol-beta) and alkyladenine DNA glycosylase (Aag) to determine the role of BER in the cytotoxic effect of temozolomide. Pol-beta-deficient cells were significantly more susceptible to killing by temozolomide than wild-type or Aag-deficient cells, a hypersensitivity likely caused by accumulation of BER intermediates. RNA interference-mediated pol-beta suppression was sufficient to increase temozolomide efficacy, whereas a deficiency in pol-iota or pol-lambda did not increase temozolomide-mediated cytotoxicity. Overexpression of Aag (the initiating BER enzyme) triggered a further increase in temozolomide-induced cytotoxicity. Enhanced Aag expression, coupled with pol-beta knockdown, increased temozolomide efficacy up to 4-fold. Furthermore, loss of pol-beta coupled with temozolomide treatment triggered the phosphorylation of H2AX, indicating the activation of the DNA damage response pathway as a result of unrepaired lesions. Thus, the BER pathway is a major contributor to cellular resistance to temozolomide and its efficacy depends on specific BER gene expression and activity.Keywords
Other Versions
This publication has 49 references indexed in Scilit:
- DNA Repair of Clustered Uracils in HeLa CellsJournal of Molecular Biology, 2005
- Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II studyJournal of Neuro-Oncology, 2005
- Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?European Journal Of Cancer, 2004
- Base Excision Repair Intermediates Induce p53-independent Cytotoxic and Genotoxic ResponsesJournal of Biological Chemistry, 2003
- Localization of the Deoxyribose Phosphate Lyase Active Site in Human DNA Polymerase ι by Controlled ProteolysisJournal of Biological Chemistry, 2003
- DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociationNature, 2003
- Primary brain tumours in adultsThe Lancet, 2003
- 5'-Deoxyribose Phosphate Lyase Activity of Human DNA Polymerase ɩ in VitroScience, 2001
- 3-Methyladenine-DNA Glycosylase (MPG Protein) Interacts with Human RAD23 ProteinsJournal of Biological Chemistry, 2000
- Contribution of O6‐methylguanine‐DNA methyltransferase to resistance to 1,3‐(2‐chloroethyl)‐1‐nitrosourea in human brain tumor‐derived cell linesMolecular Carcinogenesis, 1995